Explore the latest in adverse drug events, including postmarketing surveillance, risk mitigation, and the pharmacogenetics of safety.
This analysis investigates risk factors for immune checkpoint inhibitor–related myocarditis using a large pool of data gathered from the US Food and Drug Administration Adverse Event Reporting System database.
This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.
In May 2019 the US Supreme Court sent back to lower courts the question of whether Merck Sharpe & Dohme Corp was liable for atypical fractures from its osteoporosis drug alendronate because it did not identify the adverse effect in the product’s label. This Viewpoint discusses the legal questions of liability raised by the case and the implication of the decision for the pharmaceutical industry and for patients alleging harmed from prescription drugs.
This case series uses data from the US Food and Drug Administration’s Adverse Event Reporting System to assess the postmarketing safety profile of sipuleucel-T.
This case series report of mogamulizumab-associated cutaneous granulomatous drug eruption (CGDE) describes 12 patients with mycosis fungoides (MF) whose CGDE mimicked the MF but was followed by durable clinical MF response.
This open-label, phase 2 randomized clinical trial assesses the safety of abiraterone acetate combined with 4 glucocorticoid regimens for treatment of metastatic castration-resistant prostate cancer.
This case report describes a patient with giant cell arteritis with a necrotic scalp ulcer following treatment with nivolumab for adenocarcinoma.
This JAMA Patient Page describes use of steroid medications and the side effects that can result.
This study evaluates types and frequency of psychiatric adverse events that were reported to the US Food and Drug Administration’s Adverse Event Reporting System from 1997 through 2017 for patients taking isotretinoin.
This medical record review investigates whether use of topical clindamycin and/or oral tetracyclines during management of epidermal growth factor receptor (EGFR) inhibitor–related papulopustular eruption is associated with antibiotic-resistant bacterial infection.
This nested case-control study uses a large primary care population database in the United Kingdom to analyze the relative and absolute risk estimates of peripheral neuropathy among adults issued prescriptions for oral fluoroquinolone or amoxicillin-clavulanate antibiotics.
This case report describes changes in the electrocardiogram of a patient with anaphylaxis after an overdose of epinephrine.
This Patient Page describes how and why children may be evaluated for penicillin allergy.
This cohort study examines the pathophysiologic processes of autoimmune tissue and tumor toxic effects in patients with non–small cell lung cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: